BioSpace News Archive

NORDIC PHARMA, a SEVER Life Sciences company, announced today the submission of a New Drug Submission to Health Canada for its methotrexate auto-injector, Nordimet® for the treatment of severe disabling active rheumatoid arthritis (RA) and symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced the initiation of a Phase 1 trial evaluating its novel chimeric antigen receptor T-cell (CAR-T) therapy in ovarian cancer.

The Multiple Myeloma Research Foundation has appointed George Mulligan, Ph.D., as its new Chief Scientific Officer effective immediately.

Significant surge in geriatric population, in the last few years, has led to growing prevalence of SCAs.

Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced a corporate restructuring intended to leverage its peptide platform by prioritizing investment in its research and development pipeline programs and streamline its commercial operations.

Bluestar Genomics, Inc., today announced that its Chief Executive Officer David Mullarkey will participate in the Goldman Sachs fireside chat “The New Guard: Privates Leading The Disruption in Healthcare” on April 7, 2022 at 1:00 p.m., Eastern time.

Today, Virtualitics Inc, an advanced analytics and predictive AI company announced that the Institute for Systems Biology (ISB) will employ Virtualitics’ AI platform to enable researchers to discover the connections between vast amounts of Covid-related data for a research study on Long Covid treatment options.

International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2021.

OncoTEX Inc., an oncology company developing cancer pharmaceuticals that are tumor localizing, exhibit low side effects, target both drug-sensitive and drug-resistant solid tumors, and are MRI-detectable, today announced its novel cancer-fighting drug candidate, OxaliTEX, has received a notice of allowance for patent in Korea.

On March 29, 2022, Broncus Medical, the leader in precision interventional treatment for lung diseases in China, announced its annual results announcement for the year ended December 31, 2021.